Boehringer's survodutide hits Phase III endpoints in obesity and MASLD
Boehringer Ingelheim has released detailed Phase III data for its glucagon/GLP-1 dual agonist survodutide (BI 456906), with results from two separate trials — SYNCHRONIZE-1 and SYNCHRONIZE-MASLD — presented at the American Diabetes Association's 2026 Scientific Sessions and simultaneously published in The New England Journal of Medicine and Nature Medicine respectively.
The headline figures from SYNCHRONIZE-1, a 76-week, placebo-controlled trial in 725 adults with obesity or overweight without type 2 diabetes, showed average weight loss of up to 16.6% from baseline using the efficacy estimand, against 3.2% on placebo. A body composition sub-study using MRI measurements found that visceral fat fell by up to 34.0% relative to baseline, and liver fat by up to 63.1%. Notably, lean mass accounted for no more than 10.8% of the change in total tissue mass at the highest dose — a finding Boehringer is positioning as evidence that weight loss is predominantly driven by reductions in metabolically harmful fat rather than muscle.
MASLD trial extends the case for metabolic benefit
In SYNCHRONIZE-MASLD, a 48-week trial in 218 adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation or fibrosis, survodutide met both co-primary endpoints. Up to 84.2% of participants treated with survodutide achieved at least a 30% relative reduction in liver fat, compared with 24.3% on placebo (p<0.0001). Body weight fell by up to 12.2% versus 1.0% for placebo. A secondary endpoint showed that liver fat normalisation — defined as liver fat content below 5% — was reached by 61.0% of treated participants by week 48, against 5.7% on placebo.
Dr Lee Kaplan, Director of The Obesity and Metabolism Institute in Boston and chair of the SYNCHRONIZE programme executive committee, said the data "reveal that the glucagon/GLP-1 dual agonism of survodutide offers a promising approach for people with obesity, and for those with obesity-associated metabolic liver diseases including MASLD and MASH."
The safety profile was consistent with the known class effects of GLP-1-based therapies: gastrointestinal events — nausea, vomiting, diarrhoea, constipation — were the most commonly reported adverse events, mostly mild to moderate and occurring primarily during dose escalation. Treatment discontinuation due to GI adverse events was 19% in SYNCHRONIZE-1, compared with 2.9% on placebo. No new safety signals were identified in either trial.
Competitive landscape and regulatory context
The obesity pharmacotherapy market has become acutely competitive following the commercial success of semaglutide (Novo Nordisk's Wegovy) and tirzepatide (Eli Lilly's Zepbound), both of which have demonstrated substantial weight-loss efficacy in Phase III programmes. Survodutide's glucagon receptor co-agonism is the mechanistic differentiator Boehringer is leaning on: glucagon agonism is hypothesised to act directly on the liver to reduce hepatic fat and potentially resolve inflammation and fibrosis — a pathway not shared by pure GLP-1 agonists or the GIP/GLP-1 dual agonism of tirzepatide.
For MASH specifically, the FDA granted survodutide Breakthrough Therapy designation in September 2024 and Fast Track designation in 2021; the EMA accepted it into its PRIME scheme in November 2023. These regulatory recognitions reflect the unmet need in a liver disease space where resmetirom (Madrigal Pharmaceuticals' Rezdiffra) became the first approved MASH treatment only in 2024. Survodutide remains investigational and has not yet been submitted for approval.
Looking ahead, Boehringer plans to initiate three additional Phase IIIb studies later in 2026: SYNCHRONIZE-HERA (women's health), ELEVATE-LIVER (cardiac function in MASLD/early MASH), and SYNCHRONIZE-START (real-world titration and GLP-1 RA switching). The pivotal LIVERAGE and LIVERAGE-Cirrhosis trials, targeting MASH with advanced fibrosis, are also ongoing, with combined enrolment of approximately 3,400 patients. Full regulatory submissions will depend on those readouts, making 2027–2028 the likely window for any New Drug Application in MASH.